Identification and characterization of potent CD-19 scFv and CD-69 expression in CAR J Cells

Read full text Summarise with VIRAT
Authors: Shakir Hussain, Muhammad Zulqurnain Imran, Talha Israr, Javeria Aijaz, Yasir Raza
Cited by: 0
References: 13

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background and Objective: CD19 is the primary target for generating chimeric antigen receptor (CAR) T cells against B-cell leukemia. This study aimed to test a screening protocol for evaluating the efficacy of the CAR constructs using patient-derived B-ALL cells and CAR–expressing Jurkat (CAR-J) cells. Methodology: This study was conducted in the Molecular Research Department of Indus Hospital, Karachi, Pakistan, from January 2024 to August 2025. CAR-containing backbone plasmids (#135991, #135992, and #135993) obtained from Addgene were used to produce second-generation VSV-G pseudotyped lentiviruses. Jurkat cells were infected with these lentiviruses to create CAR-J cells. CAR-J cells were cocultured with patient-derived B-ALL CD-19-positive cells. Flow cytometry was used to evaluate CD69-APC MFI expression following co-culture (a marker of Jurkat cell activation), using APC-labelled antibodies. Increased CD69 expression in comparison with controls (uninfected Jurkat cells, acute myeloid leukemia) was taken as an indicator of the efficacy of CAR binding with CD19. Results: Only two of the three anti-CD19 CAR-J constructs induced CD69 upregulation upon co-culture with patient-derived B-ALL cells (CAR-J 135992 and CAR-J 135993) in comparison with AML controls (p = 0.0044 and p = 0.0195, respectively). When compared with uninfected Jurkat cocultured with B-ALL, all three CAR-J constructs showed significant CD69 upregulation: 135991 (p = 0.0004), 135992 (p = 0.0063), and 135993 (p = 0.0187). Conclusion: Two anti-CD19 CAR-J cell constructs (135992 and 135993) demonstrated a detectable increase in CD69 upregulation compared with AML controls, while one construct (135991) showed no activation. Once further validated, the method may have potential for screening of other CAR molecules.

Fields of Study & Subjects

CAR-T cell therapy research Immunotherapy and Immune Responses Virus-based gene therapy research

Publication details

Journal / source
Pakistan Journal of Medical Sciences
Volume
42
Issue
(ICON26)
Pages
S77–S85
Publication date
26 March 2026
Language
EN